The multitude of neuronal subtypes and extensive interconnectivity of the mammalian brain presents a substantial challenge to those seeking to decipher its functions. While the molecular mechanisms of several neuronal functions remain poorly characterized, advances in next-generation sequencing (NGS) and gene-editing technology have begun to close this gap. The clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein (CRISPR-Cas) system has emerged as a powerful genetic tool capable of manipulating the genome of essentially any organism and cell type. This technology has advanced our understanding of complex neurologic diseases by enabling the rapid generation of novel, disease-relevant in vitro and transgenic animal models. In this review, we discuss recent developments in the rapidly accelerating field of CRISPR-mediated genome engineering. We begin with an overview of the canonical function of the CRISPR platform, followed by a functional review of its many adaptations, with an emphasis on its applications for...
genetic interrogation of the normal and diseased nervous system. Additionally, we discuss limitations of the CRISPR editing system and suggest how future modifications to existing platforms may advance our understanding of the brain.

Key words: brain; Cas; Cpf1; CRISPR; nervous system; neuron

Introduction
Complex behavior is driven by extensive structural and genetic interactions in the mammalian CNS. Historically, neuroscientists have examined these interactions using a variety of histological, electrophysiological and pharmacological techniques. While indispensable, these techniques lack the specificity of targeted genetic approaches to dissect neuronal function. Recent advances have allowed the coupling of high-throughput next-generation sequencing (NGS) technologies with the cell-type specificity of modern molecular genetics to interrogate complex network interactions and behaviors at unprecedented scale and resolution. The ability to read, write, and manipulate genomes with cell-type specificity is critical, especially considering the cellular heterogeneity of various CNS structures (Chung et al., 2005).

Early attempts at targeted gene editing were performed with zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), both of which rely on programmable DNA-binding proteins coupled to active endonucleases to cleave specific DNA sequences (Kim et al., 1996; Carroll, 2011; Joung and Sander, 2013). While suitable for a variety of applications (Gaj et al., 2013), these systems have fallen out of favor for new genome editing systems due to relative disadvantages such as their extensive protein engineering requirements. Recent advances in gene editing technology have culminated in the discovery of clustered regularly interspaced palindromic repeats (CRISPR)-Cas9, a bacterial immune system for genome editing applications in eukaryotic cells (Jinek et al., 2012). While spCas9 remains the most popular CRISPR nuclease, various CRISPR-Cas systems with divergent structures and properties have been discovered. These systems are broadly categorized by their nucleosome composition, with those containing multisubunit nuclease structures pertaining to Class 1 and those composed of a single protein pertaining to Class 2. Within Class 2, systems are further subdivided into Types II, V, and VI, which pertain to DNA-targeting Cas9 and Cas12a and RNA-targeting Cas13, respectively (Shmakov et al., 2017). As Class 2 systems have been used in the majority of neuronal gene editing experiments, they will therefore be the focus of this review. Class 1 systems and their uses are described elsewhere (Cameron et al., 2019; Pickar-Oliver et al., 2019).

The prototypical CRISPR nuclease, spCas9, is an RNA-guided DNA endonuclease that relies on an RNA duplex comprised of a CRISPR RNA (crRNA) and a transactivating crRNA (tracrRNA) for its activity (Fig. 1A). CRISPR RNAs direct Cas9 enzymes to their intended genomic targets, whereas tracrRNAs are responsible for stimulating Cas9’s endonuclease activity and mediating pre-crRNA processing and maturation. Although discovered as two distinct RNAs in nature, it was experimentally determined that the essential elements of the tracrRNA-crRNA duplex could be combined into a chimeric sgRNA. Therefore, genome editing using this system only requires the Cas9 protein and the sgRNA. Cas9-DNA targeting occurs when
the Cas9-bound sgRNA hybridizes to its target-DNA proximal to a short sequence known as the protospeacer adjacent motif (PAM), which is used for target recognition. Once Cas9 binds to the genomic target site, it creates a double stranded break (DSB) approximately three bases upstream of a PAM-containing locus with sufficient crRNA complementarity. DSB formation initiates the nonhomologous end joining (NHEJ) DNA repair mechanism, which, due to the error prone nature of this repair pathway, creates insertion and deletion (indels) mutations at the DSB site (Fig. 1A). If the DSB occurs within the protein coding region of a gene, a loss of protein function can occur. The deletion of relevant codons or a shift in the reading frame often creates a truncated protein, collectively leading to a null allele/gene knock-out (KO; Jinek et al., 2012; Cong et al., 2013; Mali et al., 2013). Alternatively, if a donor DNA template is provided, homology-directed repair (HDR) can occur instead of NHEJ. This phenomenon can be harnessed to specifically modify the genome at precise loci (Fig. 1B; Cong et al., 2013; Mali et al., 2013; Wang et al., 2013). However, HDR-mediated DNA repair via existing technology remains very inefficient, and therefore, its use in non-dividing cells (i.e., neurons) in vivo has limited utility (Chu et al., 2015; Maruyama et al., 2015).

The Type V nuclease Cas12a (also known as Cpf1, CRISPR from Prevotella and Francisella 1), is a related DNA targeting enzyme that deports mechanistically from Cas9 in ways that may be advantageous. For example, unlike Cas9, Cas12a processes its own CRISPR array (crRNA precursors) into mature crRNAs, independent of any ancillary enzymes and a tracrRNA. Cas12a also recognizes a different PAM sequence (Cas12a, TTTN; Cas9, NGG), generates staggered cuts and requires a much shorter guide RNA than Cas9 (~40 nt, Cas12a; ~100 nt, Cas9). Cas12a’s compact guide RNA architecture and self-crRNA processing ability make it well suited for multiplexed gene-targeting, particularly through the use of custom arrays encoding multiple crRNAs. Recently, these properties were optimized and harnessed for large scale gene-editing, with Campa and coworkers reporting the ability to deliver and express 20 crRNAs and Cas12a from a single vector, simultaneously (Campa et al., 2019). The continued discovery and development of new CRISPR-Cas systems with advantageous properties is highly encouraging for the future of biomedical research and therapeutic development.

**Gene Disruption in the Mammalian Brain via CRISPR-Cas and NHEJ**

Targeted gene disruption is a popular approach for dissecting the functional role of many synaptic and neuronal proteins in vivo (Gray et al., 2011; Uezu et al., 2016). Historically, this has required conventional mutant germ-line engineering, which is experimentally time-consuming, can generate deleterious phenotypes, and is generally prohibitive for multigene perturbation. Gene disruption with CRISPR-Cas has been demonstrated as a promising alternative to existing gene KO strategies. Several groups have begun to apply CRISPR-Cas to disrupt genes in mature neurons in vitro and in vivo, by targeting Cas9 to specific loci and relying on NHEJ repair pathways to create indels, leading to a high rate of gene disruption (Incontro et al., 2014; Swiech et al., 2015).

The earliest studies that implemented CRISPR-Cas for neuronal gene editing in vivo established the lack of toxicity of prolonged Cas9 expression in neurons while also creating the first transgenic and viral platforms for their expression and delivery (Platt et al., 2014; Swiech et al., 2015). Using these transgenic mice, Platt and coworkers also demonstrated the high KO frequencies (84% biallelic, 9% monoallelic; NeuN) achievable in neurons transduced with AAV-sgRNAs. Swiech and coworkers sought to expand the applicability of CRISPR for broad in vivo use by adapting Cas9 for packaging into popular viral vectors for gene delivery into the brain (Swiech et al., 2015). The adeno-associated virus (AAV) DNA packaging limit (~5 kb) is a major limitation for viral delivery in vivo, therefore packaging the Cas9 transgene (~4 kb), sgRNA cassette and other necessary expression components into a single vector is infeasible. To circumvent this, Swiech and coworkers developed an AAV-CRISPR system that expresses spCas9 and its respective sgRNA from separate AAV vectors. Applying AAV-CRISPR to target various genes in vitro and in vivo recapitulated the substantial editing efficiency observed in transgenic Cas9 mice. For example, targeting methyl CpG binding protein 2 (MeCP2) in cultured neurons produced morphologic defects concurrent with MeCP2 loss of function. Furthermore, multiplexed targeting of several DNA methyltransferase genes within the dentate gyrus was capable of producing context-specific freezing deficits in mice that received contextual fear conditioning, while sparing behavioral performance in other tasks (open field test, novel object recognition, elevated plus maze).
Traditional gene editing strategies have relied heavily on engineered viral vectors for in vivo construct delivery (Yin et al., 2017). Although AAV and lentiviral (LV) vectors are widely used for their ability to stably express transgenes for extended periods, the potential drawbacks of viral delivery and prolonged Cas9 expression for therapeutic gene editing have received increased attention. For example, higher cellular concentrations of Cas9 have been shown to decrease specificity, presumably because off-target cleavage is the only possibility after all target sites have been destroyed (Davis et al., 2015). This observation has raised concerns for therapeutic developments that rely on viral gene transfer, which in the case of AAV-mediated gene expression, persists for several years after delivery (Nathwani et al., 2011; Wojno et al., 2013; Colella et al., 2018; Guilbaud et al., 2019). Engineered ribonucleoprotein complexes (RNP; Cas9 protein bound to a guide RNA) and Cas9-encapsulating nanoparticles have been developed as non-viral alternatives for local, transient CRISPR expression in the brain.

Staahl and coworkers introduced a cell permeable Cas9-RNP capable of transient and titratable gene disruption (Staahl et al., 2017). Cas9-RNPs were designed with repeating SV40 nuclear localization sequences (NLS), which have been previously reported to enhance cell-penetration (Liu et al., 2015). Preassembled Cas9-RNPs were injected into the S1 primary somatosensory cortex, the V1 primary visual cortex, the dorsal striatum and the hippocampus of Ai9tdTomato mice. Reporter activation increased in a dose-dependent manner with larger administered doses of Cas9-RNP. Furthermore, RNP injection into the dorsal striatum did not induce a significant immune response, which has been a point of concern after reports of anti-Cas9 immune responses (Chew et al., 2016).

Recently, the nanoparticle-based CRISPR-Gold system was used to target mGlur5, a metabotropic NMDA receptor involved in autism spectrum disorder (ASD)-related hyperexcitability (Lee et al., 2018). CRISPR-Gold RNPs containing mGlur5-targeting guides were infused into the striatum of fragile X mental retardation 1 (FMR1) KO mice, which significantly reduced exaggerated stereotypies (excessive digging and jumping). Analysis revealed 14.6% of striatal mGlur5 genes contained loss of function (LOF) mutations, while mGlur5 mRNA and protein levels decreased by roughly 50%. Despite modest editing efficiency, these results highlight the potential of nanoparticle-based systems to deliver CRISPR and therapeutically edit genes in the brain. While CRISPR-Gold administration was sufficient to reverse the behavioral phenotype, additional optimization of nanoparticle entry into neurons will likely expand the use of non-viral, nanoparticle-based methods for genome editing in neuroscience.

Another group engineered membrane-permeable nanocomplexes to deliver Cas9 RNPs into the brain (Park et al., 2019). CRISPR nanocomplexes were generated by fusing an amphiphilic R7L10 peptide to Cas9 RNPs to permit cellular entry. R7L10-Cas9-RNPs exhibited remarkable in vivo stability and longevity, sustaining high levels of expression for over a week, which declined below detection thresholds after three weeks. Unlike virally delivered CRISPR transgenes that remain stably expressed for extended periods, nanocomplex-delivered RNPs possess limited opportunity to perform their gene targeting functions. Remarkably, in vivo targeting of β-secretase 1 (Bace1) in the hippocampal CA3 region of 5XFAD transgenic mice produced an editing efficiency of 45% which significantly reduced Aβ plaques and Aβ42 secretion. Surprisingly, a single hippocampal injection of Bace1-targeting nanocomplexes elicited persistent improvements in contextual and associative memory three months after treatment (Park et al., 2019). While the decay rates of injected RNPs and their potential off-targeting effects remain to be determined, additional research could accelerate the development of injectable RNP therapies for focal neurologic disease.

**Germline Editing with CRISPR**

Genetically modified animals have been instrumental in understanding genetic contributions to neuronal development, function and disease. Conventionally, establishing transgenic animal strains has been a time- and labor-intensive process that requires several months and specialized facilities for completion (Capecchi, 2005). In recent years, many of these constraints have been overcome by CRISPR-Cas9 genome editing. The ability to rapidly produce transgenic animals harboring multiple germline mutations with relative ease is a significant improvement over traditional transgenic animal production approaches. For a more detailed discussion on generating transgenic/knock-in mice with CRISPR-Cas9, we direct the reader to the following articles (Yang et al., 2014; Henao-Mejia et al., 2016; Williams et al., 2016).

While the broad availability of genetically modified mice has contributed to their widespread use in biomedical science, rats remain the preferred animal model in behavioral neuroscience research. The paucity of available transgenic rat models has left an unmet demand for additional transgenic rat lines (Ellenbroek and Youn, 2016). Germline genome editing with CRISPR-Cas9 has emerged as a highly efficient method for producing transgenic strains. As such, CRISPR-Cas9 was used to generate transgenic Cre-dependent Cas9 and Cre-dependent Cas9-nickase (Cas9[D10A]) rats and an improved Cre recombinase (iCre) rat line regulated by the dopamine transporter promoter (DAT-iCre) (Bäck et al., 2019). To show that gene targeting was Cre dependent, Back and coworkers infused AAVs encoding iCre and tyrosine hydroxylase (TH)-targeting sgRNAs into the midbrain. Four weeks after infusion, a 45% and 60% decrease in TH immunoreactivity was observed in the substantia nigra and striatum, respectively. To determine the targeting efficiency achievable with double-transgenic animals (DAT-iCre+/Cas9+), AAVs encoding Manf sgRNAs were infused into the midbrain. After four weeks, only 3% of dopaminergic neurons demonstrated Manf immunoreactivity; additionally, nearly 90% of non-dopaminergic neurons remained Manf−, thereby illustrating the potential of these lines to facilitate highly specific genome editing with extremely high editing efficiencies. With the availability of neuron-specific Cre...
driver lines (GABAergic, D1, D2, parvalbumin), these Cre-dependent Cas9 rat lines present a significant advancement for future gene studies in behavioral neuroscience.

**Gene Modification in the Mammalian Brain via CRISPR-Cas and HDR**

Currently the factors governing DNA repair pathway choice remain unclear. In general, NHEJ appears to be far more efficient and active compared to HDR (Cox et al., 2015). It is generally believed that HDR is mostly restricted to the S/G2 phases of the cell cycle, which may restrict harnessing HDR’s full potential in postmitotic cells such as neurons (Saleh-Gohari and Helleday, 2004). This may be due to phase specific conditions favorable to recombination such as the presence of proximal sister chromatids or the increased expression of requisite repair machinery. Both are conditions which may preclude robust HDR activity in terminally differentiated neurons. However, this remains to be determined.

Although Cas9’s canonical function is to cleave DNA, it can also be used to introduce foreign transgenes and new sequences using HDR (Fig. 1B). Low neuronal HDR activity has largely discouraged gene-editing attempts in the brain. However, recent evidence has surfaced demonstrating the successful modification of neuronal genes in vivo. Using their newly developed CRISPR-based HDR system dubbed SLENDR (single-cell labeling of endogenous proteins via HDR system), Mikuni and coworkers targeted neural progenitors at embryonic days (E)12 and E15, when HDR should be active. Embryonic brains were subjected to in utero electroporation (IUE), to deliver sgRNAs, Cas9 coding plasmids, and a hyperactive Piggyback transposase system to allow the stable integration of these transgenes and donor templates consisting of single stranded oligonucleotides (ssODNs). This approach enabled the modification of targeted genes to possess N-terminal or C-terminal epitope tags. Remarkably, SLENDR was also capable of inserting large sequences into endogenous loci, such as the GFP-coding region, facilitating protein localization studies. The authors reported modification frequencies as high as 7.5% of neurons when targeting was performed at E12, and slightly lower levels when performed at E15. It is important to note that indel formation will occur at a much higher frequency compared to HDR-mediated sequence insertion using this system. Additionally, the authors specifically targeted the beginning and end of the protein coding regions, to reduce the chance that indel formation would have a consequence on protein structure and function.

Nishiyama and coworkers adapted the SLENDR system for viral delivery. This system, referred to as vSLENDR (AAV/CRISPR-based viral-mediated single-cell labeling of endogenous proteins via HDR system), was shown to allow HDR-mediated gene modification of neurons in the mouse adult brain (Fig. 1B). They observed gene modification efficiencies *in vivo* (Nishiyama et al., 2017) as high as ~30% of targeted neurons, which provides proof-of-principle for HDR-mediated editing in mature neurons. While encouraging, the mechanism of HDR-mediated editing requires additional characterization and subsequent optimization before it can be broadly applied for *in vivo* studies.

**Additional Gene Modification Strategies**

While broadly considered an inherently error-prone process, various NHEJ-dependent DNA-editing tools have been developed that demonstrate the remarkably high editing frequency and precision of NHEJ repair (Fig. 1C). These tools, designated homology-independent (HI) targeted insertion (HITI), Homology-Mediated End Joining (HMEJ) and Homology-independent Universal Genome Engineering (HiUGE) have been shown to effectively integrate exogenous DNA sequences at similar frequencies (20% to over 50%). The first of these, HMEJ, exploits homology-dependent (HD) processes by coupling donor templates harboring sgRNA recognition sites with targeted, Cas9-mediated DNA cleavage. HMEJ-DNA donors contain 5’ and 3’ distal sgRNA sites that, upon cleavage, release a long donor cassette which encourages integration into the cleaved genomic site. When applied to adult mouse neurons in *vivo* HMEJ produced knock-in frequencies of ~50%. Although HD strategies ensure locus specificity through extensive donor template homology, unique template production is generally restrictive for high-throughput experimentation. Therefore, unrestricted by locus homology, HI systems have gained more traction. The HITI and more recently developed HiUGE systems also exploit NHEJ repair to introduce DNA payloads. Both HITI and HiUGE incorporate similar components and mechanisms to achieve targeted transgene integration. For example, the use of a non-homologous donor vector with sgRNA recognition sequences is ubiquitous among NHEJ-mediated systems. However, HITI and HiUGE depart as HiUGE donors contain self-targeting sgRNAs, while HITI donors require sgRNA recognition sequences to be manually matched between the target and donor. The addition of a self-targeting guide RNA to HiUGE vectors permits the development of “all-in-one” donor libraries that may function complimentary with large-scale CRISPR genetic screens.

**Regulable Gene Editing with Inducible CRISPR-Cas Systems**

Germline editing with CRISPR-Cas9 has proven remarkably useful for genetically modifying animals (Li et al., 2013; Chapman et al., 2015; Remy et al., 2017). However, germline modifications can produce undesirable developmental phenotypes providing little benefit for studies interrogating gene function in adult animals. Furthermore, temporally precise manipulations may be required for studying gene function in dynamically regulated processes. In such situations it may be beneficial to deploy temporally regulable systems capable of gene editing within tightly restricted windows. Towards this aim, CRISPR-Cas9 has been combined with several other technologies to develop systems that can be regulated genetically, optically, or with small molecules (Dow et al., 2015; Zetsche et al., 2015).
Some of the first inducible CRISPR systems were regulated by components of the popular tetracycline-dependent promoter (Tet) system (Dow et al., 2015; de Solis et al., 2016), which can be regulated in Tet-on (rtTA) and Tet-off (tTA) configurations (Fig. 2; Gossen and Bujard, 1992; Gossen et al., 1995). de Solis and coworkers developed the first doxycycline (Dox)-inducible Cas9-based editing system that saw use in the brain. First, Cas9 was placed under the control of the Dox-dependent TRE3G promoter in an attempt to temporally regulate Cas9 expression and subsequent genome editing (de Solis et al., 2016). However, TRE3G-driven Cas9 exhibited leaky expression in vitro, prompting the development of regulable sgRNA expression vectors, which successfully regulated gene-editing events in a Dox-dependent manner. To determine whether this Dox-regulable CRISPR-Cas9 system was suitable for in vivo applications, AAV vectors encoding Cas9 and Dox-inducible sgRNAs were infused into the basolateral amygdala (BLA). In vivo genome-editing analysis revealed that only animals receiving Dox contained indels at the target locus. Additionally, Dox-inducible and constitutively expressed systems exhibited near identical levels of gene editing, demonstrating that spatiotemporally precise editing is achievable in the brain without significant loss of efficiency. Additional Cre and Dox-inducible CRISPR systems have been developed based on the smaller SaCas9 endonuclease. For further discussion of the SaCas9 orthologue and these inducible tools, we direct the reader to (Kumar et al., 2018; Zhou et al., 2018b).

While the conditional Tet- and Cre-based systems are frequently used to restrict gene expression temporally and spatially, their specificity and regulation is largely transcriptionally mediated. In cases where swift gene-editing is desirable, it is beneficial to reduce the response rate of the system. Post-translationally regulated processes circumvent the de novo transcription and translation involved in transcriptionally mediated responses, permitting a more rapid response to dynamic cellular environments. Additionally, reducing the permissible window for gene-targeting events could significantly reduce the off-target modifications reported with constitutively active Cas9. Several inducible Cas9 enzymes have been developed whose activities are post-translationally regulated with small molecules (Fig. 2; Davis et al., 2015; Liu et al., 2016a). These small molecule-responsive systems use the human estrogen receptor ligand-binding domain (ERT) fused to Cas9 to trigger gene editing events in the presence of the ERT ligand 4-hydroxytamoxifen (4-HT). Davis and coworkers introduced a 4-HT-inducible Cas9 nuclease whose enzymatic activity was inhibited by a strategically placed, self-splicing intein (Intein-Cas9; Davis et al., 2015). Intein-Cas9 was engineered such that its enzyme activity would only be restored after administration of the ERT ligand 4-hydroxytamoxifen (4-HT).
4-HT, which activates intein-protein self-splicing and permits Cas9’s adoption of a catalytically active form. A related 4-HT inducible Cas9 enzyme was introduced in 2016, dubbed “iCas.” However, this system departs from its predecessor by employing ERT2 as a subcellular carrier versus a covalent inhibitor. As the ERT2 ligand binding domain permits translocation into the nucleus when bound by 4-HT, fusing multiple copies of the ERT2 domain to Cas9 enables bidirectionally regulable genome editing in human cells. Both of these systems demonstrated improved editing specificities over wild-type Cas9, although iCas9 exhibited lower background activity and higher on-target editing when benchmarked against intein-Cas9. While intein-Cas9 and iCas9 show promise for studying dynamic processes in the brain, to our knowledge, they have yet to see use in such experiments.

Advances in photoinducible protein biology have culminated in the development of systems that can control gene-editing and transcription with blue-light irradiation (Fig. 2; Nihongaki et al., 2015; Polstein and Gersbach, 2015). Nihongaki and coworkers achieved photoinducible gene editing by conjugating fragments of a Cas9 nuclease to protein elements of a dimerizing, light responsive system dubbed “magnets” (Kawano et al., 2015). The fungal-derived magnet system consists of two photoinducible protein elements termed “positive magnet” (pMag) and “negative magnet” (nMag), which are named on the basis of their electrostatic properties (Kawano et al., 2015). This system demonstrated that gene editing could be bidirectionally regulated by light irradiation, albeit with modest indel frequencies and a relatively slow response time (maximal editing ~48 h). As these limitations may limit paCas9’s usefulness in vivo, additional engineering and optimization are likely required before this technology can be robustly applied in animal studies. While light inducible and optogenetic technologies are widely used in neuroscience research, photoactivatable gene-editors have yet to be applied to the nervous system.

Genomic Regulation with Nuclease-Deficient Cas9
Cas9’s capabilities have expanded beyond conventional genome editing by adapting the system into a programmable DNA-binding module (Fig. 3). To achieve this, Cas9’s catalytic activity was abolished by introducing point mutations into the RuvC1 (D10A) and HNH (H840A) domains to generate nuclease deficient or dCas9. Catalytically-inactive Cas9 retains DNA-binding capability with no apparent loss of targeting or binding specificity (Qi et al., 2013). As discussed below, dCas9-effector fusions provide seemingly endless applications for non-mutagenic genome modification, including transcriptional regulation, epigenome editing, cellular imaging, and RNA interference (RNAi).

Transcriptional Regulation with dCas9
CRISPR-based transcriptional regulators provide researchers with the ability to assess the functional relevance of specific genes in a variety of neuronal contexts. By manipulating endogenous loci, CRISPR-based overexpression and gene silencing strategies circumvent the shortcomings of cDNA overexpression and RNAi-mediated silencing such as potential protein mislocalization or widespread off-targeting. The first systems endowing activator and repressor capabilities to the CRISPR platform used fusions of tetrameric herpes simplex viral protein 16 (VP64), the NF-κB trans-activating subunit p65 (p65), or the Krüppel-associated box domain of Kox1 (KRAB) to dCas9 (Gilbert et al., 2013; Fig. 3E). When directed to promoter or enhancer sequences, dCas9-VP64 and dCas9-KRAB were capable of inducing or suppressing gene-specific transcription, respectively. These capabilities encouraged their ready adoption for mapping putative cis-regulatory elements in neurodevelopment and neurodegeneration studies (Frank et al., 2015; Heman-Ackah et al., 2016; Huang et al., 2017). Although this first generation of transcriptional regulators could modestly alter transcription, several reports demonstrated that gene expression could be amplified with the provision of multiple sgRNAs per targeted promoter (Gilbert et al., 2013; Maeder et al., 2013; Konermann et al., 2015; Savell et al., 2019). This observation suggested that the overall copy number and enzyme cooperativity of the recruited effectors was responsible for differences in gene expression. Capitalizing on this observation, other groups developed additional CRISPR activator (CRISPRa) and CRISPR interference (CRISPRi) systems with enhanced transcriptional regulatory capabilities (Tanenbaum et al., 2014; Chavez et al., 2015; Konermann et al., 2015). These second-generation systems employ diverse scaffold architectures to recruit transcriptional regulators and maximize effector potency and recruitment.

Early second-generation systems employed an epitope-based scaffolding strategy to increase activator recruitment known as SUperNova (SunTag; Fig. 3C; Tanenbaum et al., 2014). The SunTag scaffold is a peptide array composed of tandem repeating GCN4 epitopes. Transcriptional regulators conjugated to short-chain variable fragments (scFv) with high affinity for the GCN4 epitope can effectively bind the SunTag scaffold, facilitating the formation of multimeric regulatory structures at targeted DNA sequences. Essentially the system is designed to recruit many VP64 transcriptional activation domains to the promoter to enhance transcriptional activation. Indeed, expressing dCas9-SunTag with scFv-bound VP64 activators dramatically increased targeted gene expression compared to that achieved by dCas9-VP64.

Another study (Konermann et al., 2015) examined the regulatory potential of sgRNAs designed to recruit transcriptional activators using RNA aptamers (Fig. 3B). Analysis of sgRNA secondary structures identified regions that were non-interacting with the Cas9 endonuclease and found that mutating distal base pairs in these regions had no influence on DNA binding or cleavage. By substituting sgRNA stem loops with MS2 aptamers that could recruit MS2 coat proteins (MCPs) fused to p65 and heat shock factor 1 (HSF1), it was determined that dCas9-VP64 could upregulate transcription at significantly higher
Figure 3. Transcriptional and epigenetic regulation with CRISPR-Cas transcriptional control can be achieved by fusing various transcription regulating enzymes to catalytically inactive Cas9 (dCas9). The CRISPR-based activators SunTag, VPR, SAM, and SPH employ various architectures to recruit transcription activating molecules. A, VPR deploys traditional peptide linkers to fuse the tripartite VP64, p65, and Rta effector to dCas9. B, The synergistic activator mediator (SAM) uses the MS2 RNA aptamer to recruit MCPs fused to a p65-HSF1 domain to induce transcription. C, The SunTag system utilizes the a GCN4-epitope array to localize VP64 activators to transcription start sites (TSSs). D, Relatedly, the SPH system uses the SunTag scaffolding array to recruit p65-HSF1 dimers in lieu of VP64. The dCas9-KRAB (E) and the improved dCas9-KRAB-MeCP2 (F) transcriptional repressors use similar strategies inhibit transcription. G, dCas9 fused to the DNA methyltransferase 3A (DNMT3A) enzymatic domain can de-novo
methylate CpG dinucleotides in a programmable manner. **H**, dCas9 fused to ten-eleven translocation’s (TET1) catalytic domain facilitates successive cytosine oxidation and demethylation at methylated CpG sites. dCas9-DNMT3A/TET1 can effectively regulate gene transcription by targeting CpG containing promoter regions for epigenetic modification. dCas9 C-terminally fused to the catalytic core of the human p300 acetyltransferase (p300(COO) **J** or histone deacetylase 8 (HDAC8) **J** can regulate the acetylation status of histone 3 lysine 27 (H3K27) residues to regulate transcription from promoters and both distal and proximal enhancers.

levels when co-expressed with RNA aptamer-containing sgRNAs versus standard sgRNAs.

A separate group screened putative activator domains for gene activation potency, identifying VP64, p65 and the Epstein–Barr virus R transactivator (Rta) as the most potent transcriptional activators. However, dCas9-p65 and dCas9-Rta both exhibited lower transcription rates than the original dCas9-VP64 chimera. To overcome this, combinations of activators were fused with the aim of cooperatively inducing higher gene expression (**Chavez et al., 2015**). Using dCas9-VP64 as a starting framework, a tripartite fusion of VP64-p65-Rta (VPR; **Fig. 3A**) was tethered to dCas9 and subsequently assayed for induction capacity, which revealed that gene expression was upregulated between 22- and 320-fold when compared with dCas9-VP64.

Second-generation activators were screened for maximal induction of Ascl1 and Neurod1 genes in HEK293T cells, revealing SAM (**Konermann et al., 2015**), SunTag (**Tanenbaum et al., 2014**), and VPR (**Chavez et al., 2015**) as the most potent gene activators. Subsequent assays revealed SAM as the most consistent in activating high levels of gene expression. Notably, the increased transcription of several tested genes reached orders of magnitude above that induced by dCas9-VP64 (**Chavez et al., 2016**).

While newly developed CRISPRa systems underwent validation in several common cell types, few have seen any use in neuronal contexts. Savell and coworkers have recently introduced LV vectors capable of robust neuronal VPR expression **in vitro** and **in vivo** (**in vivo discussion continued below; Savell et al., 2019**). Gene overexpression assays in primary cultured neurons demonstrated VPR’s ability to robustly overexpress single or multiple genes with high specificity. Notably, multiplexed gene activation with VPR recapitulated earlier reports of sgRNA-dose responsiveness. Effective activation was demonstrated using an individual sgRNA and significantly increased with the provision of multiple unique sgRNAs.

In contrast to transcriptional activators, few dCas9 repressors capable of enhanced transcriptional downregulation have been developed. Recognizing this deficit, Yeo and coworkers proceeded to perform a similar screen to identify dCas9-repressors capable of robustly inhibiting gene expression (**Yeo et al., 2018**). Of the screened transcriptional repressors, the bipartite dCas9-KRAB-MeCP2 fusion emerged as the most potent (**Fig. 3F**).

**Regulating Transcription In Vivo with dCas9**

Ectopic gene overexpression mediated through viral vector delivery is a popular strategy to investigate neuronal gene regulation (**Lentz et al., 2012**; **Haggerty et al., 2020**). As previously described, numerous CRISPRa systems have been developed, enabling the potent activation of multiple genes in various tissues types. However, until recently, these technologies have been limited to **in vitro** applications because of the difficulty associated with the efficient delivery of multiple large transgenes **in vivo**. Recently, elements of the SAM and SunTag system were combined to develop a new dCas9-based transcriptional activator, dCas9-SunTag-p65-HSF1 (SPH; **Fig. 3D**), for **in vivo** gene regulation (**Zhou et al., 2018a**). To develop the SPH platform, the VP64 tetramers in the SunTag system were replaced with the p65-HSF1 domains from the SAM system. When combined, these components potently induced gene expression, surpassing the SunTag, VPR, and SAM activators.

In order to circumvent the difficulties associated with viral delivery of large, multicomponent systems to the nervous system, the authors generated a transgenic mouse line harboring a Cre-dependent SPH system. Considering that cell-type and circuit-specific multiplex strategies will likely be required to successfully interrogate gene networks **in vivo**, Zhou and coworkers performed feasibility experiments on SPH’s multiplex gene activation capabilities. Using a combination of AAV vectors encoding Cre recombinase (hSyn-Cre and CamKIIα-Cre) and sgRNA arrays targeting multiple genes (eight coding genes and two long noncoding RNAs), Zhou and coworkers successfully overexpressed several targeted genes simultaneously. When coupled with existing genome wide CRISPRa sgRNA libraries, these SPH mice provide a useful tool for endogenous gene overexpression and genome wide screening in the brain.

Savell and colleagues sought to optimize the previously developed dCas9-VPR activator for behavioral neuroscience by developing neuron-optimized viral vectors capable of potent, multiplexed gene expression **in vivo**. By examining VPR expression under the control of several promoters, they were able to identify and produce a LV system that permitted robust VPR expression **in vitro** and **in vivo** under the control of the neuron-specific Synapsin promoter. This neuron-optimized LV VPR system was applied in various neuronal contexts and was notably capable of potent, isoform-specific induction of various BDNF transcripts **in vivo** (**Savell et al., 2019**).

Until recently, RNAi and conditional Cre-loxP systems have been the predominate methods used for gene knock-down and KO, respectively. However, evidence documenting the significant off-target effects of short hairpin RNA (shRNA) and small interfering RNA (siRNA) has accumulated (**Castanotto and Rossi, 2009**; **Jackson and Linsley, 2010**; **de Solis et al., 2015**). Alternative methods for gene knock-down such as CRISPR-based repressors have been proposed, due to their ability to potently silence gene expression within various contexts.
However, the application of CRISPRi technology in neurons has seen limited use \textit{in vivo}.

Recently, a LV-based CRISPRi system was developed for use in the mammalian brain (Fig. 3E). Using the dCas9-KRAB repressor, synaptogamin I (Syt1), vesicle-associated membrane protein I (Vamp1), syntaxin 1A (Stx1a), and synaptosome-associated protein 25 (Snap25), genes responsible for vesicular neurotransmitter release, were targeted in cultured hippocampal neurons. To compare the efficiency of CRISPRi and RNAl-mediated knock-down, sgRNAs and shRNAs were tested for each target gene. CRISPRi produced \textasciitilde{} 90\% reduction in mRNA and protein levels of all genes targeted, compared to a modest reduction produced by RNAi. Additionally, whole-cell patch-clamp recordings of CRISPRi-targeted hippocampal neurons revealed significant reductions in EPSCs, as expected from disruption of the neurotransmitter release pathway (Zheng et al., 2018).

Numerous studies have reported the potential for Cas9 endonucleases to bind off-target sites (Kuscu et al., 2014; Wu et al., 2014). This, coupled with the observed potency of the dCas9-KRAB repressor, raises concerns for severe off-target silencing. The authors used a \textquotedblleft pseudo-target fishing strategy\textquotedblright{} to determine the frequency of off-targets by expressing dCas9-KRAB with sgRNAs containing unique mismatches with the Syt1 locus. This strategy revealed that Syt1 expression levels remain largely unchanged, indicating that mismatched sgRNAs were incapable of efficiently directing dCas9-KRAB to the Syt1 locus (Zheng et al., 2018).

As cell-type specificity is essential for the interrogation of gene and cell function in the brain, the dCas9-KRAB repression system was modified to restrict targeting to glutamatergic (CaMKII\textalpha{}-dCas9-KRAB) or GABAergic (VGAT-dCas9-KRAB) neurons. LV infusion into the dentate gyrus revealed a roughly 20\% transduction rate of neurons confined to the granule layer. Analysis of dCas9-KRAB\textsuperscript{-}DG neurons revealed that Syt1 expression was completely abolished in a cell-type specific manner. Likewise, whole-cell patch-clamp revealed that EPSCs within CaMKII\textalpha{}-expressing neurons were almost completely abolished, with a similar reduction in GABAergic neuron IPSCs (Zheng et al., 2018).

Targeting Syt1 within glutamatergic and GABAergic neurons enables altering of the inhibitory-excitatory (I\textendash{}E) ratio within the hippocampus. As the hippocampus is implicated in various forms of learning and memory (LaBar and Cabeza, 2006), the authors subjected mice to multiple spatial and associative learning tasks after CRISPRi mediated I\textendash{}E shifting. Animals receiving CaMKII\textalpha{}-dCas9-KRAB (shift towards inhibition) exhibited significant performance reductions in spatial memory related tasks (Morris water maze, Barnes Maze, T maze) compared with animals receiving VGAT-dCas9-KRAB (shift towards excitation). In tests of associative memory (fear conditioning), CaMKII\textalpha{} driving animals demonstrated reduced freezing levels in response to a cued stimulus (tone) in contrast to VGAT driving animals which exhibited slightly enhanced freezing, illustrating that alterations of the I\textendash{}E ratio within the hippocampus could bidirectionally regulate spatial and contextual fear memory (Zheng et al., 2018).

**CRISPR-Based Epigenome Editors**

DNA methylation is vitally involved in neurodevelopment and in dynamic gene regulation across various networks in the CNS (Smith and Meissner, 2013). Cytosine methylation within promoter regions permits the controlled regulation of various processes ranging from basic gene transcription to higher-order functions such as learning, memory and cognition. Historically, epigenetic studies have been incapable of determining the functional relevance of specific methylation events due to the limitations of the methylation-inhibiting small molecules 5-aza-cytidine and 5-aza-2\'-deoxycytidine (Heerboth et al., 2014). Although these compounds could be locally injected to induce regional CpG hypomethylation, these shortcomings are largely prohibitive for the precise investigation of disorders such as Angelman’s, Fragile X, Rett syndrome, and Prader–Willi syndrome, all which exhibit significant neurologic phenotypes and aberrant CpG methylation (Butler, 2009). Recent advances in epigenome engineering technology have produced CRISPR-based epigenome editors that couple the programmable targeting of CRISPR with enzymes involved in the DNA methylation pathway (Fig. 3G\textendash{}J; Liu et al., 2016b, 2018a; Lei et al., 2017).

As dynamic DNA methylation has been proposed to regulate activity-dependent gene expression, Liu and coworkers sought to determine whether their LV dCas9-TET1 system could induce brain-derived neurotrophic factor (BDNF) expression by targeting the BDNF IV promoter for demethylation in cultured primary neurons (Fig. 3H; Liu et al., 2016b). Neuronal dCas9-TET1 expression successfully increased BDNF expression 6-fold. However, \textit{“no sgRNA”} controls also produced a nearly 2-fold increase in BDNF expression, demonstrating this system’s potential for non-specific gene induction. CRISPR-epigenome editors have also been used preclinically for therapeutic studies. For example, dCas9-TET1 was used to demethylate the CGG trinucleotide expansion in the 5’ UTR of the Fmr1 gene in models of fragile X syndrome (FXS; Persico and Napoliioni, 2013; Liu et al., 2018a), dCas9-TET1 targeting to the Fmr1 5’ UTR in \textit{in vitro}-derived FXS neurons significantly reduced CGG trinucleotide hypermethylation and the associated hyperexcitable phenotype. Remarkably, dCas9-TET1-treated inducible pluripotent stem cell (iPSC)-induced FXS neurons retained high levels of FMRF expression months after their engraftment into live mouse brains.

Beyond the transcriptional regulation mediated by dynamic DNA methylation, histone modifications gatekeep gene expression by altering chromatin conformation and the accessibility of \textit{cis}-regulatory elements to DNA binding proteins (Yarrington et al., 2018). CRISPR-based epigenome editors have been used to uncover the functional importance of discrete regulatory elements (Hilton et al., 2015; Chen et al., 2019). Using dCas9-p300 and dCas9-HDAC8 (Fig. 3J), the histone modifications at the second enhancer (Enh2) of the neuronal immediate early gene
(IEG) Fos were shown to fine tune the degree of activity-induced transcription. In other words, the type of histone modification installed by p300/HDAC8 could slightly increase or decrease activity-dependent Fos transcription. However, inducing a heterochromatic state with HDAC8 could not completely silence Fos activity, and inducing a euchromatic or “protranscriptional” state was insufficient to induce Fos transcription without neuronal activity. This observation contrasts the constitutive gene activation mediated by other CRISPRa systems, which if targeted to Enh2, would presumably induce Fos without neuronal activity. The effectiveness of CRISPR-based epigenome editors highlights the potential for these new tools to elucidate the functional relevance of non-coding and epigenetically regulated elements to animal behavior, neuronal function and disease.

**Engineering the Neuronal Transcriptome with RNA-Targeting CRISPR Effectors**

Programmable DNA-targeting Cas9 nucleases have been used for in vivo gene studies. However, tools enabling the study of RNA function are severely lacking. Recently, the diverse group of Class 2 CRISPR-Cas systems has been expanded to include the Type VI, RNA-targeting Cas13 family of effectors (Abudayyeh et al., 2016, 2017). Despite their recency, RNA-targeting CRISPR systems have been engineered for targetable RNA visualization, knock-down, base-editing, and in vitro isoform manipulation (Figs. 4, 5; Abudayyeh et al., 2017; Cox et al., 2017; Konermann et al., 2018). The Cas13 family of endonucleases are characterized by a single-effector protein containing two higher eukaryotes and prokaryotes nucleotide-binding (HEPN) ribonuclease (RNase) domains (Abudayyeh et al., 2016). Unlike their DNA-targeting counterparts, Cas13 effectors do not require tracrRNAs for pre-crRNA processing, nor do they require PAM sequences for nucleic acid targeting and non-self-recognition. Instead, sequences that are enriched proximally to protospacer targeting sites are referred to as protospacer flanking sequences (PFSs). Notably, several Cas13 variants have been shown to not require a PFS for RNA cleavage (Cox et al., 2017). Multiple studies have reported a large amount of divergence amongst the Type VI family, often reporting little sequence conservation among Cas13 nucleases other than the characteristic HEPN RNase domains; for a more complete discussion of their individual properties we suggest reviewing (Shmakov et al., 2017).

Numerous studies have compared the knock-down ability of multiple Cas13 subtypes and orthologues to RNAs, which have overwhelmingly demonstrated that Cas13’s RNA knock-down capabilities are superior to those of shRNAs (Abudayyeh et al., 2017; Cox et al., 2017; Konermann et al., 2018). Additionally, the recently discovered Cas13d effector, *Ruminococcus flavefaciens*-Cas13d (CasRx; Fig. 4A), has been shown to more effectively silence gene expression than other well-established methods such as CRISPRa (Konermann et al., 2018). When targeted to the endogenous *B4GALNT1*, *ANXA4*, and *HOTTIP* genes in HEK293FT cells, CasRx demonstrated a remarkable median knock-down efficiency of 96% compared with 53% knock-down produced with sequence-matched shRNAs. Furthermore, CasRx did not generate any detectable off-target transcriptional changes, which starkly contrasts shRNA-induced silencing of an excess of 500–900 off-target genes (Konermann et al., 2018). CasRx also outperformed CRISPRa (dCas9-KRAB) mediated repression, which produced a median 53% knock-down rate when targeted to the same genes. Other recently described Cas13 subtypes have been shown to robustly knock-down RNA in mammalian cells. Compared to Cas13a (LwaCas13a-msfGFP-NLS; Abudayyeh et al., 2017) and Cas13b (PspCas13b-NES; Cox et al., 2017), CasRx demonstrated greater transcript knock-down ability (median knock-down rates; Cas13a, 80%; Cas13b, 66%; CasRx, 97%). Remarkably, of 14 sgRNAs targeted to both coding and non-coding RNA, CasRx yielded at least ~80% transcript knock-down, suggesting that CasRx could be used to regulate any RNA in the cell.

Several degenerative diseases have been linked to mutations within individual pre-mRNA elements. For instance, mutations within exons 45–55 or exon 23 of the Dystrophin gene produce the muscle degeneration associated with
Duchenne muscular dystrophy (DMD; Ousterout et al., 2015; Long et al., 2016). Likewise, neurodegenerative tauopathies such as Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) is associated with point mutations in exon 10 of the MAPT gene, which determines which Tau protein isoform is expressed in neurons (Boeve and Hutton, 2008). As previous studies have reported success in models of DMD using exon-skipping strategies (Nelson et al., 2019), Konermann and coworkers tested whether dCasRx could efficiently drive isoform selection by developing a dCasRx-RNA splice effector fusion (Fig. 4B).

Pre-mRNA splicing is mediated by interactions between cis-acting elements (splice acceptor/donor sites, intronic branchpoint nucleotides, etc.) and the trans-acting spliceosome (Matera and Wang, 2014). Within the cohort of pre-mRNA interacting molecules are the heterogeneous nuclear RNPs (hnRNPs), a ubiquitously expressed group of splice factors that facilitate alternative splicing by inhibiting exon exclusion (Wang et al., 2015). The hnRNPa1-CTD was fused to dCasRx and targeted to several putative splicing elements, which successfully induced exon-skipping in a fluorescence splicing reporter. In order to determine whether skipping exon 10 of the MAPT gene could decrease the accumulation of pathogenic (isoform 4R) tau, cortical neurons differentiated from patient-derived iPSCs were transduced with AAV encoding dCasRx-hnRNPa1 and three exon 10 targeting sgRNAs. dCasRx-hnRNPa1 mediated exon-skipping was shown to reduce 4R/3R ratios by 50%, a level similar to uninfected controls (Konermann et al., 2018).

These results demonstrate the ability of Type VI, RNA-targeting Cas13 effectors for enhanced RNAi and manipulation. In the past, applications of dCas13 effector fusions have been limited by their large size. Therefore, CasRx’s short coding sequence (~2.9 kb) makes it highly suited for use in AAV vectors. As described above, the CasRx fusion and three sgRNAs fell below AAV packaging limitations, a characteristic that may inspire the future development of CasRx-based effectors that are capable of elucidating RNA function in the brain.

**Base and Prime Editing**

Existing CRISPR technologies equip researchers with a powerful, multifunctional platform to investigate a staggering number of biological questions, however these tools are not without drawbacks. DSBs created by Cas9 nucleases often result in haphazard DNA repair and indel formation, which can frequently produce extensive sequence heterogeneity and yield several unwanted or deleterious DNA products. Technologies have been developed that circumvent problematic DSBs and imprecise cellular DNA repair processes through the use of enzymes (Fig. 5) that can alter RNA and DNA nucleotides in situ, or more recently, prime editors that can faithfully install edits through reverse-transcription of an RNA template (Fig. 6). These technologies, termed base editors, rely on dCas9 fusions to nucleobase deaminases to directly install point mutations without the need for DSBs. Existing base editors are collectively able to catalyze all possible transition mutations (C to T and A to G, point mutations) in DNA, with recent developments in RNA base editing allowing the conversion of A to I, and C to U bases as well. DNA and RNA base editors are extensively discussed in Rees and Liu (2018). As of yet, no studies have reported the use of base editors in any neuronal context. However, the growing number of single nucleotide polymorphisms (SNPs) implicated in psychiatric and neurologic diseases and the finding that the mRNAs of various neuronal ion channels and synaptic receptors undergo RNA editing may prompt the future use of these tools in neuroscience laboratories (Behm and Öhman, 2016).

Prime editors present the latest advance in precision gene editing. Anzalone and coworkers introduced a Cas9 nickase (Cas9n)-based system that couples the DSB-free
editing strategy pioneered with base-editors to an sgRNA-based RNA donor template (Fig. 6; Anzalone et al., 2019), a strategy similar to one recently introduced in yeast (Sharon et al., 2018). Prime editors are multicomponent systems comprised of a chimeric Cas9n-reverse transcriptase and a prime editing guide RNA (pegRNA). Both the target locus and the desired DNA edit are encoded on the pegRNA, which harbors the standard Cas9 sgRNA components and a 3′ extended RNA template. Cas9n cleavage of the PAM-containing strand allows donor-template invasion and hybridization, which permits RNA-template reverse transcription and effective installation of the desired edit. This prime editing strategy was shown to successfully introduce broad classes of edits with lower indel frequencies than Cas9-mediated HDR in multiple cell types in vitro, including a modest editing frequency (6–8%) in primary neuronal cultures. Although a promising development, the frequency of genome-wide off targets and unintended reverse transcription products remain unknown. This, in concert with the modest editing frequency achieved with the latest prime editor, may preclude its immediate use in vivo. Nonetheless, this technology presents an exciting new development towards achieving high-fidelity, corrective gene editing with CRISPR.

**CRISPR Screens**

The recent exponential advances in NGS technologies and the easy design and production of large numbers of unique sgRNAs has facilitated the high-throughput investigation of various psychiatric and neurodegenerative disorders, cancer, and essential gene functions through large-scale CRISPR screens (Fig. 7). CRISPR-mediated screens combine high-throughput, single-cell sequencing technologies with genome-wide sgRNA targeting libraries optimized for gene KO (Sanjana et al., 2014; Doench et al., 2016; Morgens et al., 2017; Wang et al., 2018; Liu et al., 2019), activation (Horlbeck et al., 2016; Joung et al., 2017; Chong et al., 2018; Liu et al., 2018b; Sanson et al., 2018), and silencing (Horlbeck et al., 2016; Liu et al., 2017; Sanson et al., 2018) applications. Recent applications of CRISPR-screening have produced new experimental pipelines that permit the unambiguous contribution of risk-associated genes to disease phenotypes (Thyme et al., 2019) and the determination of cellular-lineage and heredity in developmental studies (McKenna et al., 2016; Raj et al., 2018). For example, CRISPR-Cas9 was recently used to perform a mutant-phenotyping screen on schizophrenia-associated genes identified in human genome-wide association studies (GWAS; Thyme et al., 2019). Cas9 was used to mutagenize several risk-associated genes in developing zebrafish. These mutants were then subjected to behavioral and structural analysis which allowed Thyme and co-workers to successfully uncover phenotypes for multiple understudied genes. A separate zebrafish study deployed a large-scale CRISPR-Cas9 technique (GESTALT; see McKenna et al., 2016 for additional background) combined with single-cell RNA-seq (scRNA-Seq) to determine cellular fate and lineage characteristics in developing brains. Paired with an inducible Cas9, DNA barcodes harboring
specific target sequences were used to indicate whether DNA editing occurred in a specific cell; because genomic bar code expression results in cellular progeny with identical barcode sequences, this allowed Raj and coworkers to determine the lineage histories for a plethora of cell types in the developing zebrafish brain.

While most screens are performed in vitro or ex vivo, two CRISPR-Cas9 mediated in vivo screens have recently been reported in the brain (Chow et al., 2017; Jin et al., 2019). A recent in vivo screen (Perturb-Seq, first described by Dixit et al., 2016) aimed at systematically uncovering the phenotypes of a large panel of ASD-related genes was performed by coupling cell-type specific transcriptomics and a lentivirus-mediated sgRNA library targeting 35 putative ASD-risk genes. Ventricularly injecting LV-sgRNA libraries into developing embryos in utero permitted postnatal, single-cell transcriptional profiling and identification of multiple gene clusters from cortical and striatal tissue. CRISPR knock out coupled with a scRNA-seq readout readily enabled differential gene identification, subsequent perturbation and phenotyping for a number of ASD-risk genes involved in distinct molecular pathways across variant cell types.

The earliest reported in vivo screen was directed at investigating the functional and tumorigenic consequences of significantly mutated genes (SMGs) that were previously identified in tumor samples taken from human glioblastoma multiforme (GBM) patients (Chow et al., 2017). A pooled AAV-sgRNA library (mouse homolog tumor suppressor library (mSTG)) targeting various risk-genes was hippocampally or ventricularly infused into mice, which produced GBM-characteristic tumor growth at four months postinjection. Histologic, transcriptomic and genetic characterization of AAV-CRISPR-mediated GBM tumors, in vivo and ex vivo, permitted the successful identification and correlation of single and co-occurring tumor drivers to GBM mutations identified in human patients.

Although CRISPR-based screens are heavily used in oncology research (Hart et al., 2015; Tzelepis et al., 2016; Chow et al., 2017), these tools have garnered significantly less attention for large-scale genetic studies in disease-relevant cell types such as differentiated neurons. Tian and coworkers recently performed several CRISPRi screens to elucidate functional contributions of various genes to cell survival, differentiation, transcriptional regulation and morphology in human iPSC (hiPSC)-derived neurons (Tian et al., 2019). In an initial survival screen, dCas9-BFP-KRAB and the LV H1 sgRNA library were used to target ~2300 genes comprising the “druggable genome.” CRISPRi-mediated gene knock-down uncovered a strong neuronal dependence on sterol/cholesterol metabolism genes and enhanced neuron survival when members of the integrated stress response (DLK, JNK, PERK) were knocked down. Tian and coworkers also performed screens that identified common regulators of variant transcriptional programs in iPSCs and neurons, as well as several genes that contributed to neuronal longevity and morphology.

**Existing Challenges for CRISPR Gene Editing**

Despite the explosive progress of CRISPR-mediated genome engineering in the last decade, significant challenges for clinical and preclinical applications remain. For example, concerns regarding CRISPR’s immunogenicity, targeting efficiency, fidelity and optimal delivery will need to be addressed before CRISPR can fulfill its clinical and research potential.

CRISPR delivery in vivo has been accomplished virally, with RNPs and nanoparticles. For preclinical studies using small animals, these delivery methods are sufficient, since experiments can be conducted where useful data can be generated by targeting relatively small body areas. Viruses and RNPs can deliver their necessary cargo to regions of this size reasonably well. However, improvements can be made to increase the ease of delivery and the area of tissue that could be effectively targeted with CRISPR systems. For example, conventional AAVs and LVs need to be stereotactically injected intracranially to gain access to the brain and usually will not transduce more than a few cubic millimeters of tissue. More recently, AAVs with modified capsids have been developed that can cross the blood brain barrier, so they can be administered systemically and transduce brain cells (Chan et al., 2017). Although these developments are encouraging, they still need more development for clinical utility. Notably, non-human primate research and clinical human studies will generally benefit from less invasive routes of delivery that can target larger regions of the brain. This will be an important hurdle to overcome if CRISPR is to ever realize its full potential of treating CNS diseases.

For any gene modification technique, its specificity and accuracy are paramount, especially for clinical
applications. While high-fidelity SpCas9 variants have been developed (Kleinstiver et al., 2016; Slaymaker et al., 2016; Chen et al., 2017; Casini et al., 2018; Chatterjee et al., 2018; Hu et al., 2018), the off-targeting frequencies gene KO in preclinical applications, SpCas9 characterized CRISPR nucleases following systemic (IV) administration clinical studies have described the immunogenicity of have received extensive scrutiny. Recently, various pre-clinically, aspects of its safety for use in human therapies. However, as CRISPR becomes implemented significant enthusiasm for the future of personalized gene therapies. However, as CRISPR becomes implemented clinically, aspects of its safety for use in human therapies have received extensive scrutiny. Recently, various pre-clinical studies have described the immunogenicity of CRISPR nucleases following systemic (IV) administration to laboratory mice (Chew et al., 2016; Nelson et al., 2019). Host anti-vector and transgene responses are discussed elsewhere (Sun et al., 2003; Rabinowitz et al., 2019; Wang et al., 2019). Additionally, preexisting adaptive immunity against S. pyogenes and Staphylococcus aureus Cas9 have also been reported in humans (Charlesworth et al., 2019). However, these findings are unsurprising given the high frequency at which these bacteria infect humans (Lowy, 1998; Roberts et al., 2012). While SpCas9 and SaCas9 remain two of the most broadly used CRISPR enzymes, new orthologues derived from non-pathogenic bacterial species may be required for human therapies where preexisting immunity is a concern. Alternatives such as orthologue specific-epitope engineering or short term suppression (Chew et al., 2016) may theoretically ameliorate immune responses in the short-term. However, the long-term expression of AAV-mediated therapies and their potential for genome insertion at DSB sites (Miller et al., 2004; Hanlon et al., 2019), may limit the feasibility of immunosuppressive approaches.

The low efficiency of precise editing (corrective editing via HDR, prime editing, etc.), in neurons is another significant hurdle for the use of CRISPR for neuroscience research and human therapy. The available data indicate that precise editing occurs at relatively low levels in neurons, limiting the utility of these methods and currently making them unlikely to have any benefit clinically. Although precise editing occurs relatively infrequently in most cell types compared to NHEJ-mediated indel formation, disorders that affect mitotically active cell populations may be more amenable to HDR-based therapies. For example, hematopoietic progenitor cells can be genetically modified ex vivo, clonally selected efficiency, expanded and then re-implanted, essentially bypassing the issue of inefficient HDR mediated precision editing. In another example it was recently demonstrated that AAV-CRISPR could be delivered via tail injection in a mouse model of hereditary tyrosinemia Type 1 (HTI) to correct genetic mutations within the liver (Yin et al., 2014). Although only a small percentage of hepatocytes (<1%) harbored the therapeutic edit, the gene correction provided a fitness advantage to edited cells, which allowed them to repopulate the liver. Unfortunately, given that neurons are postmitotic, precise, CRISPR-mediated editing has limited utility for the foreseeable future until methods are developed to increase its efficiency.

Conclusions and Future Directions

The CRISPR-Cas system has emerged as a highly adaptable platform with extensive utility in multiple areas of biomedical and basic science. Given its ability to target nearly any gene or RNA transcript, alter gene expression and modify epigenetic states with high specificity, CRISPR-Cas represents an invaluable tool helping drive the rapid pace of discovery in biological sciences. While early studies only demonstrated its use in peripheral tissues, recent efforts have produced CRISPR-Cas systems amenable for use in the CNS. Additionally, the development of CRISPR-expressing animals, as well as the discovery of AAV-compatible orthologues, have provided substantial tools for probing neuronal function at multiple levels of analysis. While newly developed CRISPR-transgenics may be crossed with existing Cre-driving lines, novel CNS-optimized tools will likely require viral vector encoding and delivery. Challenges associated with viral vectors such as packaging constraints, low virus infectivity and low gene editing efficiencies remain limiting factors for using CRISPR in the brain. In order to maximize the therapeutic and research potential of available systems, existing delivery methods must be optimized and new, more effective ways of introducing these systems must be developed. Undoubtedly, future improvements and applications of CRISPR-Cas technology will surface. Despite these challenges, recent advances in CRISPR-Cas technology have provided researchers with powerful new tools for engineering the neuronal genome.

References

Abudayyeh OO, Gootenberg JS, Konermann S, Joung J, Slaymaker IM, Cox DB, Shmakov S, Makarova KS, Semenova E, Minakhin L, Severinov K, Regen A, Lander ES, Koonin EV, Zhang F (2016) C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science 353:aaf5573.

Abudayyeh OO, Gootenberg JS, Esvelt-Klettcher P, Han S, Joung J, Beloanto JJ, Verdine G, Cox DBT, Kellner MJ, Regen A, Lander ES, Voytas DF, Ting CY, Zhang F (2017) RNA targeting with CRISPR-Cas13. Nature 550:280–284.

Anzalone AV, Randolph PB, Davis JR, Sousa AA, Kobljan LW, Levy JM, Chen PJ, Wilson C, Newby GA, Raguram A, Liu DR (2019) Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576:149–157.

Bäck S, Necarsulmer J, Whitaker LR, Cok L, Kivula P, Heathward EJ, Fortuno LV, Zhang Y, Yeh CG, Baldwin HA, Spencer MD, Mejias-Aponte CA, Pickel J, Hoffman AF, Spivak CE, Lupica CR, Underhill SM, Amara SG, Domansky A, Attilla JE, et al. (2019) Neuron-specific genome modification in the adult rat brain using CRISPR-Cas9 transgenic rats. Neuron 102:105–119.e8.

Behm M, Öhman M (2016) RNA editing: a contributor to neuronal dynamics in the mammalian brain. Trends Genet 32:165–175.
Casini A, Olivieri M, Montagna C, Petris G, Montagna C, Reginato G, Maule G, Carroll D (2011) Genome engineering with zinc-finger nucleases. Biotechnol 37:1471–1477.

Chapman KM, Medrano GA, Jaichander P, Chaudhary J, Waits AE, Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart M, Williams C, Toh MS, Irby MJ, Edwards LS, Lin CH, Owen ALG, Künne T, van der Oost J, et al. (2019) Harnessing type I CRISPR-Cas systems for genome engineering in human cells. Nat Biotechnol 37:1471–1477.

Campa CC, Weisbach NR, Santinha AJ, Incarnato D, Platt RJ (2019) Multiplexed genome engineering by Cas12a and CRISPR arrays encoded on single transcripts. Nat Methods 16:887–893.

Boeve BF, Hutton M (2008) Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). Arch Neurol 65:460–464.

Butler MG (2009) Genomic imprinting disorders in humans: a mini-review. J Assist Reprod Genet 26:477–486.

Cameron P, Coons MM, Kionpe SE, Lied AM, Smith SC, Vidal B, Donohoue PD, Rosstein T, Kohrs BW, Nyer DB, Kennedy R, Bank LM, Williams C, Toh MS, Iby MJ, Edwards LS, Lin CH, Owen ALG, Künne T, van der Oost J, et al. (2019) Harnessing type I CRISPR-Cas systems for genome engineering in human cells. Nat Biotechnol 37:1471–1477.

Dixit A, Parnas O, Li B, Chen J, Fulco CP, Jerby-Arnon L, Marjanovic ND, Dionne D, Burks T, Raychowdhury R, Adamson B, Norman TM, Lander ES, Weissman JS, Friedman N, Regev A (2016) Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens. Cell 167:1853–1866.e17.

Doench JG, Fusi N, Mullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE (2016) Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol 34:184–191.

Dominguez AA, Lim WA, Qi LS (2016) Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation. Nat Rev Mol Cell Biol 17:5–15.

Dow LE, Fisher J, O’Rourke KP, Muley A, Kastenhuber ER, Livshits G, Tschaharganeh DF, Socci ND, Lowe SW (2015) Inducible in vivo genome editing with CRISPR-Cas9. Nat Biotechnol 33:390–394.

Ellenbroek B, Youn J (2016) Rodent models in neuroscience research: is it a rat race? Dis Model Mech 9:1079–1087.

Frank CL, Liu F, Wijayatunge R, Song L, Biegler MT, Yang MG, Vokey CM, Safl A, Gersbach CA, Crawford GE, West AE (2015) Regulation of chromatin accessibility and Zic binding at enhancers in the developing cerebellum. Nat Neurosci 18:647–656.

Gaj T, Gersbach CA, Barbas CF 3rd (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31:397–405.
Gray JA, Shi Y, Usui H, During MJ, Sakimura K, Nicoll RA (2011) Distinct modes of AMPA receptor suppression at developing synapses by GluN2A and GluN2B: single-cell NMDA receptor subunit deletion in vivo. Neuron 71:1085–1101.

Guilbaud M, Devaux M, Cousiné C, Le Duff J, Toromanoff A, Vandammme C, Jaulin N, Germoux G, Larcher T, Mouiller P, Le Guillou B, Adjalii O (2019) Five years of successful inducible transgene expression following locoregional adeno-associated virus delivery in nonhuman primates with no detectable immunity. Hum Gene Ther 30:802–813.

Haggerty DL, Grecco GG, Reeves KC, Atwood B (2020) Adeno-associated viral vectors in neuroscience research. Mol Ther Methods Clin Dev 17:69–82.

Hanlon KS, Kleinstiver BP, Garcia SP, Zaborowski MP, Volak A, Ingelsson M, Chamberlain JS, Corey DP, Aryee MJ, Joung JK, Breakfield XO, Maguire CA, Gyborg Y (2019) High levels of AV vector integration into CRISPR-induced DNA breaks. Nat Commun 10:4439.

Hart T, Chandrashekar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, Mis M, Zimmermann M, Fradet-Turcotte A, Sun S, Mero P, Dirks S, Sidhu R, Roth FP, Rissland OS, Durocher D, Angers S, Moffat J (2018) Use of epigenic drugs in disease: an overview. Genet Epigenet 6:9–19.

Heman-Ackah SM, Bassett AR, Wood MJ (2016) Precision modulation of neurodegenerative disease-related gene expression in human iPSC-derived neurons. Sci Rep 6:28420.

Henao-Mejia J, Williams A, Rongvaux A, Stein J, Hughes C, Flavell RA (2016) Generation of genetically modified mice using the CRISPR-Cas9 genome-editing system. Cold Spring Harbor Protoc 2016:pdb.prot050704.

Hilton IB, D’ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE, Gersbach CA (2015) Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnology 33:510–517.

Horlbeck MA, Gilbert LA, Villalta JE, Adamson B, Pak RA, Chen Y, Fields AP, Park CY, Corn JE, Kampmann M, Weissman JS (2016) Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. Elife 5.

Hu JH, Miller SM, Geurts MH, Tang W, Chen L, Sun N, Zeina CM, Gao X, Rees HA, Lin Z, Liu DR (2018) Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature 556:57–63.

Huang YA, Zhou B, Wernig M, Sudhof TC (2017) ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and Aβ secretion. Cell 168:427–441.e21.

Incontro S, Asensio CS, Edwards RH, Nicoll RA (2014) Efficient, complete depletion of synaptic proteins using CRISPR. Neuron 83:1051–1057.

Jackson AL, Linsley PS (2010) Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9:57–67.

Jin X, Simmons SK, Guo AX, Shetty AS, Ko M, Nguyen L, Robinson E, Oyler P, Curry N, Deangelis G, Lodato S, Levin JZ, Regev A, Zhang F, Arlotta P (2019) In vivo Perturb-seq reveals neuronal and glial abnormalities associated with autism risk genes. bioRxiv 791525.

Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337:816–821.

Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Braingh MD, Sanjana NE, Zhang F (2017) Genome-scale CRISPR-Cas9 knockdown and transcriptional activation screening. Nat Protoc 12:828–863.

Joung JK, Sander JD (2013) TALENS: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14:49–55.

Kawano F, Suzuki H, Furuya A, Sato M (2015) Engineered pairs of distinct photoswitches for optogenetic control of cellular proteins. Nat Commun 6:6256.

Kim YG, Cha J, Chandrasegaran S (1996) Hybrid restriction enyzmes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci USA 93:1156–1160.

Kleinsteve BP, Preve MS, Tsai SQ, Topkar VV, Nguyen NT, Zheng Z, Gonzales AP, Li Z, Peterson RT, Yeh JR, Aryee MJ, Joung JK (2015) Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523:481–485.

Kleinsteve BP, Pattanayak V, Preve MS, Tsai SQ, Nguyen NT, Zheng Z, Joung JK (2016) High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529:490–495.

Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, Hsu PD, Habib N, Gootenberg JS, Nishimasu H, Nureki O, Zhang F (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517:583–588.

Korver P, Lofy P, Bridjeau NJ, Oki J, Shokhirev MN, Hsu PD (2018) Translorme engineering with RNA-targeting type VI-D CRISPR effectors. Cell 173:665–676.e4.

Kumar N, Stanford W, de Solis C, Aradhana, Abraham ND, Dao TJ, Thaseen S, Sairavi A, Gonzalez CEU, Ploski JE (2018) The development of an AAV-based CRISPR SaCas9 genome editing system that can be delivered to neurons in vivo and regulated via doxycyclin and Cre-recombinase. Front Mol Neurosci 11:413.

Kuscu C, Arslan S, Singh R, Thorpe J, Adli M (2014) Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnology 32:677–683.

Labar KS, Cabeza R (2006) Cognitive neuroscience of emotional memory. Nat Rev Neurosci 7:54–64.

Lee B, Lee K, Panda S, Gonzales-Rojas R, Chong A, Bugay V, Park HM, Brenner R, Murthy N, Lee HY (2018) Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours. Nat Biomed Eng 2:497–507.

Lei Y, Zhang X, Su J, Jeong M, Gundry MC, Huang YH, Zhou Y, Li W, Goodell MA (2017) Targeted DNA methylation in vivo using an engineered dCas9-MS2 fusion protein. Nat Commun 8:16026.

Lentz TB, Gray SJ, Samulski RJ (2012) Viral vectors for gene delivery to the central nervous system. Neurobiol Dis 48:179–188.

Li W, Teng F, Li T, Zhou Q (2013) Simultaneous generation and germ-line transmission of multiple gene mutations in rats using CRISPR-Cas systems. Nat Biotechnology 31:684–686.

Liu J, Gaj T, Walenc MM, Barbas CF 3rd (2015) Improved cell-penetrating zinc-finger nucleases proteins for precision genome engineering. Mol Ther Nucleic Acids 4:e232.

Liu J, Srivivasan J, Li CY, Ho IL, Ross J, Shaheen M, Wang G, Yao W, Deem A, Bristow C, Hart T, Draetta G (2019) Pooled library screening with multiplexed Cpf1 library. Nat Commun 10:3144.

Liu KI, Ramlit MN, Woo CW, Wang Y, Zhao T, Zhang X, Yim GR, Chong BY, Gowher A, Chua MZ, Jung J, Lee JH, Tan MH (2016a) A chemical-inducible CRISPR-Cas9 system for rapid control of genome editing. Nat Chem Biol 12:980–987.

Liu XS, Wu H, Ji X, Stelzer Y, Wu X, Czuderna S, Shu J, Dadon D, Young RA, Jaenisch R (2016b) Editing DNA methylation in the mammalian genome. Cell 167:233–247.e7.

Liu SJ, Horlbeck MA, Cho SW, Birk HS, Malatesta M, He D, Attellino FJ, Villalta JE, Cho MY, Chen Y, Mandegar MA, Olvera MP, Gilbert LA, Conklin BR, Chang HY, Weissman JS, Lim DA (2017) CRISPR-based genome-scale identification of functional long noncoding RNA loci in human cells. Science 355:eaa7.1117.

Liu XS, Wu H, Krizsch M, Wu X, Graef J, Muffat J, Hnisz D, Li CH, Yuan B, Xu C, Li Y, Vershkov D, Cacace A, Young RA, Jaenisch R (2018a) Rescue of fragile X syndrome neurons by DNA methylation editing of the FMR1 gene. Cell 172:979–992.e6.

Liu Y, Yu C, Daley TP, Wang F, Cao WS, Bhat S, Lin X, Still C, 2nd, Liu H, Zhao D, Wang H, Xie XS, Ding S, Wong WH, Wernig M, Qi LS (2018b) CRISPR activation screens systematically identify factors that drive neuronal fate and reprogramming. Cell Stem Cell 23:758–771.e8.
Long C, Amoasi L, Mireault AA, McAnally JR, Li H, Sanchez-Ortiz E, Bhattacharyya S, Shelton JM, Bassel-Duby R, Olson EN (2016) Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351:400–403.

Lowy FD (1998) Staphylococcus aureus infections. N Engl J Med 339:520–532.

Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK (2013) CRISPR RNA-guided activation of endogenous human genes. Nat Methods 10:977–979.

Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM (2013) RNA-guided human genome engineering via Cas9. Science 339:823–826.

Maruyama T, Dougan SK, Truttman MC, Bilate AM, Ingram JR, Ploegh HL (2015) Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat Biotechnol 33:538–542.

Matera AG, Wang Z (2014) A day in the life of the spliceosome. Nat Rev Mol Cell Biol 15:108–121.

McKenna A, Findlay GM, Gagnon JA, Horwitz MS, Schier AF, Matera AG, Wang Z (2014) A day in the life of the spliceosome. Nat Rev Mol Cell Biol 15:108–121.

McKenna A, Findlay GM, Gagnon JA, Horwitz MS, Schier AF, Matera AG, Wang Z (2014) A day in the life of the spliceosome. Nat Rev Mol Cell Biol 15:108–121.

Mikuni T, Nishiyama J, Sun Y, Kamasawa N, Yasuda R (2016) High-throughput, high-resolution mapping of protein localization in mammalian brain by in vivo genome editing. Cell 165:1803–1817.

Miller DG, Petek LM, Russell DW (2004) Adeno-associated virus vectors integrate at chromosome breakage sites. Nat Genet 36:767–773.

Morgens DW, Wainberg M, Boyle EA, Ursu O, Araya CL, Tsui CK, Haney MS, Hess GT, Han K, Jeng EE, Li A, Snyder MP, Greenleaf WJ, Kundaje A, Bassik MC (2017) Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens. Nat Commun 8:15178.

Nathwani AC, Tuddenham EGD, Rangarajan S, Rosales C, McIntosh AA, Morgens DW, Wainberg M, Boyle EA, Ursu O, Araya CL, Tsui CK, Haney MS, Hess GT, Han K, Jeng EE, Li A, Snyder MP, Greenleaf WJ, Kundaje A, Bassik MC (2017) Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens. Nat Commun 8:15178.

Pickar-Oliver A, Black JB, Lewis MM, Mutchnick KJ, Klann TS, Gilcrest KA, Sitten JL, Miano J, Barrera A, Bartelt LC, Reddy TE, Beisel CL, Barrangou R, Gersbach CA (2019) Targeted transcriptional modulation with type I CRISPR-Cas9 systems in human cells. Nat Biotechnol 37:1493–1501.

Platt RJ, Chen S, Zhou Y, Iymi MJ, Swiech L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, Jovanovic M, Graham DB, Jhunjhunwala S, Heidenreich M, Xavier RJ, Langer R, Anderson DG, Haochen N, Regev A, Feng G, Sharp PA, Zhang F (2014) CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159:440–455.

Polstein LR, Gersbach CA (2015) A light-inducible CRISPR-Cas9 system for control of endogenous gene activation. Nat Chem Biol 11:198–200.

Qu LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA (2013) Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152:1173–1183.

Rabinowitz J, Chan YK, Samulski RJ (2019) Adeno-associated virus (AAV) versus immune response. Viruses 11:102.

Raj B, Wagner DE, McKenna A, Pandey S, Klein AM, Shendure J, Gagnon JA, Schier AF (2018) Simultaneous single-cell profiling of lineages and cell types in the vertebrate brain. Nat Biotechnol 36:442–450.

Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, Zetsche B, Shalem O, Wu X, Makarova KS, Koonin EV, Sharp PA, Zhang F (2015) In vivo genome editing using Staphylococcus aureus Cas9. Nature 520:186–191.

Rees HA, Liu DR (2018) Base editing: precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet 19:770–788.

Remy S, Chenouard V, Tesson L, Usai C, Menoret S, Brusselle L, Herlicz JM, Nguyen TH, Bellien J, Merot J, De Glan A, Gavagnancelli C, Concordet JP, Anecon I (2017) Generation of n-germated rats by delivery of CRISPR/Cas9 protein and donor DNA into intact zygotes using electroporation. Sci Rep 7:16554.

Roberts AL, Connolly KL, Kirse DJ, Evans AK, Poehling KA, Peters TR, Reid SD (2012) Detection of group A Streptococcus in tonsils from pediatric patients reveals high rate of asymptomatic streptococcal carriage. BMC Pediatr 12:3.

Saleh-Gohari N, Heledday T (2004) Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. Nucleic Acids Res 32:3683–3688.

Sanjana NE, Shalem O, Zhang F (2014) Improved vectors and genome-wide CRISPR systems for screening. Nat Methods 11:783–784.

Sanson KR, Hanna HE, Hegde M, Donovan KR, Strand C, Sullender ME, Vainberg EW, Goodale A, Root DE, Piccioni F, Doench JG (2018) Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat Commun 9:5416.

Savell KE, Bach SV, Zipperle MY, Revanna JS, Goska NA, Tuscher JJ, Duke GG, Sultun FA, Burke JN, William D, Ivanov L, Day JJ (2019) A neuron-optimized CRISPR/dCas9 activation system for robust and specific gene regulation. eNeuro 6.

Sharon E, Chen SA, Kshosa NM, Smith JD, Pritchard JK, Fraser HB (2018) Functional genetic variants revealed by massively parallel precise genome editing. Cell 175:544–557.e6.

Shmakov S, Smargon A, Scott D, Cox D, Pyzocha N, Yan W, Abudayeh OO, Gootenberg JS, Makarova KS, Wolf YI, Severinov K, Zhang F, Koonin EV (2017) Diversity and evolution of class 2 CRISPR-Cas systems. Nat Rev Microbiol 15:169–182.

Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F (2016) Rationally engineered Cas9 nucleases with improved specificity. Science 351:84–88.

Smith ZD, Meissner A (2013) DNA methylation: roles in mammalian development. Nat Rev Genet 14:204–220.

Staahl BT, Benekahreddy M, Coulon-Bainier C, Banfal AA, Floor SN, Sabo JK, Urnes C, Munares GA, Ghosh A, Doudna JA (2017) Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes. Nat Biotechnol 35:431–434.

Sun JY, Anand-Jawa V, Chatterjee S, Wong KK (2003) Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther 10:964–976.

Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J, Sur M, Zhang F (2015) In vivo interrogation of gene function in the...
mammalian brain using CRISPR-Cas9. Nat Biotechnol 33:102–106.
Tanenbaum ME, Gilbert LA, Qi LS, Weissman JS, Vale RD (2014) A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell 159:635–646.
Thyme SB, Pieper LM, Li EH, Pandey S, Wang Y, Morris NS, Sha C, Choi JW, Herrera KJ, Soucy ER, Zimmerman S, Randlett O, Greenwood J, McCarroll SA, Schier AF (2019) Phenotypic landscape of schizophrenia-associated genes defines candidates and their shared functions. Cell 177:478–491.e20.
Tian R, Gachechiladze MA, Ludwig CH, Laurie MT, Hong JY, Nathaniel D, Prabhu AV, Fernandopulle MS, Patel R, Abshari M, Ward ME, Kampmann M (2019) CRISPR interference-based platform for multimodal genetic screens in human iPSC-derived neurons. Neuron 104:239–255.e2.
Tian R, Gachechiladze MA, Ludwig CH, Laurie MT, Hong JY, Nathaniel D, Prabhu AV, Fernandopulle MS, Patel R, Abshari M, Ward ME, Kampmann M (2019) CRISPR interference-based platform for multimodal genetic screens in human iPSC-derived neurons. Neuron 104:239–255.e2.
Tzalepis K, Koike-Yusa H, de Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, Gozdecka M, Ohnishi S, Cooper J, Patel M, McKerrell T, Chan J, Domingues AF, Gallipoli P, Teichmann S, Ponstingl H, et al. (2016) A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell Rep 17:1193–1205.
Uezu A, Kanak DJ, Bradshaw TW, Soderblom EJ, Catavero CM, Burette AC, Weinberg RJ, Soderling SH (2016) Identification of an elaborate complex mediating postsynaptic inhibition. Science 353:1123–1129.
Wang D, Tai PWL, Gao G (2019) Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov 18:358–378.
Wang G, Chow RD, Ye L, Guzman CD, Dai X, Dong MB, Zhang F, Sharp PA, Platt RJ, Chen S (2018) Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR-mediated direct in vivo screening. Sci Adv 4:eaao5508.
Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R (2013) One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153:910–918.
Wang Y, Liu J, Huang BO, Xu YM, Li J, Huang LF, Lin J, Zhang J, Min QH, Yang WM, Wang XZ (2015) Mechanism of alternative splicing and its regulation. Biomed Rep 3:152–158.
Williams A, Henao-Mejia J, Flavell RA (2016) Editing the mouse genome using the CRISPR-Cas9 system. Cold Spring Harb Protoc 2016: pdb.top087536.